Cangene acquires Twinstrand Therapeutics
This article was originally published in Scrip
Executive Summary
Cangene has acquired privately held Twinstrand Therapeutics for Cdn$1.5 million ($1.3 million). The deal brings in products, technologies and financial attributes, said Cangene.